

ASGR2 antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI10664

Product Information

ApplicationWB, IHCPrimary AccessionP07307

Other Accession NM 001181, NP 001172

Reactivity Human, Pig
Predicted Human
Host Rabbit
Clonality Polyclonal
Calculated MW 35092

Additional Information

Gene ID 433

Alias Symbol HL-2, HBXBP, ASGPR2, ASGP-R2, CLEC4H2

Other Names Asialoglycoprotein receptor 2, ASGP-R 2, C-type lectin domain family

4 member H2, Hepatic lectin H2, HL-2, ASGR2, CLEC4H2

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 100 ul of distilled water. Final anti-ASGR2 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions ASGR2 antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name ASGR2

Synonyms CLEC4H2

Function Mediates the endocytosis of plasma glycoproteins to which the terminal

sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N- acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and


transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.

Cellular Location Membrane; Single-pass type II membrane protein.

References

Yik,J.H., et al., (2002) J.Biol.Chem.277(43),40844-40852Reconstitution and Storage:For short term use, store at 2-8C up to 1 week. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.

Images



Human Spleen



WB Suggested Anti-ASGR2 Antibody Titration: 4.0µg/ml Positive Control: HepG2 cell lysate ASGR2 is supported by BioGPS gene expression data to be expressed in HepG2

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.